Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
- PMID: 30267116
- PMCID: PMC6351514
- DOI: 10.1007/s00259-018-4158-1
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
Abstract
Purpose: Therapy with [177Lu-DOTA,Tyr3]octreotate is effective in patients with grade I/II metastasized and/or inoperable bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy and safety of salvage treatment with [177Lu-DOTA,Tyr3]octreotate.
Methods: Patients with progressive bronchial NET or GEP-NET were selected for re-(re)treatment if they had benefited from initial peptide receptor radionuclide therapy (I-PRRT) with a minimal progression-free survival (PFS) of 18 months. Patients received an additional cumulative dose of 14.8 GBq of [177Lu-DOTA,Tyr3]octreotate over two cycles per retreatment with PRRT (R-PRRT) or re-retreatment with PRRT (RR-PRRT).
Results: The safety and efficacy analyses included 181 patients and 168 patients, respectively, with bronchial NET or GEP-NET. Overall median follow-up was 88.6 months (95% CI 79.0-98.2). Median cumulative doses were 44.7 GBq (range 26.3-46.4 GBq) during R-PRRT (168 patients) and 59.7 GBq (range 55.2-≤60.5 GBq) during RR-PRRT (13 patients). Objective response and stable disease, as best response, were observed in 26 patients (15.5%) and 100 patients (59.5%) following R-PRRT, and in 5 patients (38.5%) and 7 patients (53.8%) following RR-PRRT, respectively. Median PFS was 14.6 months (95% CI 12.4-16.9) following R-PRRT and 14.2 months (95% CI 9.8-18.5) following RR-PRRT. Combined overall survival (OS) after I-PRRT plus R-PRRT and RR-PRRT was 80.8 months (95% CI 66.0-95.6). Grade III/IV bone marrow toxicity occurred in 6.6% and 7.7% of patients after R-PRRT and RR-PRRT, respectively. Salvage therapy resulted in a significantly longer OS in patients with bronchial NET, GEP-NET and midgut NET than in a nonrandomized control group. The total incidence of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) was 2.2%. No PRRT-related grade III/IV nephrotoxicity was observed.
Conclusion: A cumulative dose of up to 60.5 GBq salvage PRRT with [177Lu-DOTA,Tyr3]octreotate is safe and effective in patients with progressive disease (relapse-PD) following I-PRRT with [177Lu-DOTA,Tyr3]octreotate. Safety appears similar to that of I-PRRT as no higher incidence of AML or MDS was observed. No grade III/IV renal toxicity occurred after retreatment.
Keywords: Efficacy; Gastroenteropancreatic; Neuroendocrine; PRRT; Safety; Salvage.
Conflict of interest statement
Conflicts of interest
E.P. Krenning is an advisor to Advanced Accelerator Applications, S.A., Saint-Genis Pouilly, France.
All other authors declare no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not describe any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6351514/bin/259_2018_4158_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6351514/bin/259_2018_4158_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6351514/bin/259_2018_4158_Fig3_HTML.gif)
Similar articles
-
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20. Clin Cancer Res. 2017. PMID: 28428192
-
Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.BMC Cancer. 2019 Aug 8;19(1):788. doi: 10.1186/s12885-019-6000-y. BMC Cancer. 2019. PMID: 31395036 Free PMC article.
-
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742. doi: 10.1007/s00259-018-4209-7. Epub 2018 Nov 30. Eur J Nucl Med Mol Imaging. 2019. PMID: 30506283 Clinical Trial.
-
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.
-
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.Nucl Med Rev Cent East Eur. 2018;21(2). doi: 10.5603/NMR.2018.0019. Nucl Med Rev Cent East Eur. 2018. PMID: 29741203 Review.
Cited by
-
Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.J Gastrointest Cancer. 2024 May 23. doi: 10.1007/s12029-024-01065-z. Online ahead of print. J Gastrointest Cancer. 2024. PMID: 38780680
-
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Curr Oncol Rep. 2024 May;26(5):538-550. doi: 10.1007/s11912-024-01526-5. Epub 2024 Apr 6. Curr Oncol Rep. 2024. PMID: 38581469 Free PMC article. Review.
-
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.Theranostics. 2024 Jan 1;14(3):940-953. doi: 10.7150/thno.91268. eCollection 2024. Theranostics. 2024. PMID: 38250038 Free PMC article. Review.
-
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.Front Endocrinol (Lausanne). 2023 Nov 20;14:1187870. doi: 10.3389/fendo.2023.1187870. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38053729 Free PMC article. Review.
-
Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center.Cureus. 2023 Oct 23;15(10):e47506. doi: 10.7759/cureus.47506. eCollection 2023 Oct. Cureus. 2023. PMID: 38021538 Free PMC article.
References
-
- Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–4663. doi: 10.1200/JCO.2009.22.8510. - DOI - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous